PTU - Polskie Towarzystwo Urologiczne
list of articles:

CODE: 8.1 - Synergistic cytotoxic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), photodynamic therapy and/or cisplatin on bladder cancer cells in vitro
Article published in Urologia Polska 2006/59/Suplement 1.

authors

Ewelina Szliszka 1, Zenon P. Czuba 1, Wojciech Król 1, Aleksander Sieroń 2
1 Katedra i Zakład Mikrobiologii i Immunologii w Zabrzu ¦AM w Katowicach
2 Katedra i Klinika Chorób Wewnętrznych i Medycyny Fizykalnej, Centrum Diagnostyki i Terapii Laserowej w Bytomiu, ¦AM w Katowicach

summary

Introduction. TRAIL, a member of the tumor necrosis factor superfamily is a promising novel, biologically active molecule that selectively induces apoptosis in cancer cells with no toxicity against normal tissues. However, not all transformed cells are susceptible to TRAIL. TRAIL-resistant tumor cells can be sensitized to TRAIL induced apoptosis by anticancer agents.
Objectives. We investigated the cytotoxicity effect of TRAIL in combination with photodynamic therapy (PDT) and/or cisplatin on TRAIL-resistant bladder cancer cell line.
Materials and methods. The human bladder transitional cancer cell (TCC) line 647V was relatively resistant to TRAIL. The 647V cells were incubated with rhs SuperKillerTRAIL at the concentrations 5, 10, 50 ng/mL for 18 hours with or without pretreatment PDT or cisplatin. Cytotoxicity was determined by a 1-day microculture tetrazolium dye (MTT) assay.
Results. Our results confirmed that 647V cells were resistant to TRAIL (34.5 ?2.5% cytotoxicity). We therefore examined the cytotoxic effect of low dose PDT and/or cisplatin in combination with 50 ng/mL TRAIL on TCC cell line. Treatment 647V cells with PDT and/or cisplatin significantly augmented TRAIL induced cytotoxicity (54.1 ?1.1% - 91 ?2.4%).
Conclusions. We report that photodynamic therapy and/or chemotherapeutic drugs overcome TRAIL-resistance in TCC. The obtained results indicate that synergistic effect TRAIL and anticancer agents may provide the basis for a new therapeutic approach to induce cancer cells death in bladder tumor.